JCR Pharmaceuticals Announces Completion of Acquisition of ArmaGen, Inc.

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced that it has completed the previously announced acquisition of ArmaGen, Inc., a privately held US biopharmaceutical company headquartered in San Diego, California (“ArmaGen”). As a result of this acquisition, ArmaGen has become a wholly-owned subsidiary of JCR, providing JCR with a full access to its portfolio of intellectual property rights applicable to a broad disease spectrum, including lysosomal storage disorders (LSDs) in several key markets that ArmaGen owns.

Read the full article: JCR Pharmaceuticals Announces Completion of Acquisition of ArmaGen, Inc. //

Source: https://www.prnewswire.com/news-releases/jcr-pharmaceuticals-announces-completion-of-acquisition-of-armagen-inc-301047260.html

Scroll to Top